Sökning: onr:"swepub:oai:DiVA.org:uu-333824" > The role of infecti...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05343naa a2200553 4500 | |
001 | oai:DiVA.org:uu-333824 | |
003 | SwePub | |
008 | 171129s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3338242 URI |
024 | 7 | a https://doi.org/10.1007/s00134-017-4780-62 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Tängdén, Thomasu Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)thota437 |
245 | 1 0 | a The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections |
264 | c 2017-04-13 | |
264 | 1 | b Springer Science and Business Media LLC,c 2017 |
338 | a print2 rdacarrier | |
520 | a Critically ill patients with severe infections are at high risk of suboptimal antimicrobial dosing. The pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobials in these patients differ significantly from the patient groups from whose data the conventional dosing regimens were developed. Use of such regimens often results in inadequate antimicrobial concentrations at the site of infection and is associated with poor patient outcomes. In this article, we describe the potential of in vitro and in vivo infection models, clinical pharmacokinetic data and pharmacokinetic/ pharmacodynamic models to guide the design of more effective antimicrobial dosing regimens. Individualised dosing, based on population PK models and patient factors (e.g. renal function and weight) known to influence antimicrobial PK, increases the probability of achieving therapeutic drug exposures while at the same time avoiding toxic concentrations. When therapeutic drug monitoring (TDM) is applied, early dose adaptation to the needs of the individual patient is possible. TDM is likely to be of particular importance for infected critically ill patients, where profound PK changes are present and prompt appropriate antibiotic therapy is crucial. In the light of the continued high mortality rates in critically ill patients with severe infections, a paradigm shift to refined dosing strategies for antimicrobials is warranted to enhance the probability of achieving drug concentrations that increase the likelihood of clinical success. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
653 | a Individualised dosing | |
653 | a Antibiotics | |
653 | a Pharmacokinetics | |
653 | a Pharmacodynamics | |
653 | a Mathematical modelling | |
700 | 1 | a Martin, V. Ramosu Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.4 aut |
700 | 1 | a Felton, T. W.u Univ South Manchester Hosp, Intens Care Unit, Manchester, Lancs, England.4 aut |
700 | 1 | a Nielsen, Elisabet I.,d 1973-u Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)elnie838 |
700 | 1 | a Marchand, S.u INSERM, Pole Biol St, U1070, Poitiers, France.;Univ Poitiers, UFR Med Pharm, Poitiers, France.4 aut |
700 | 1 | a Brueggemann, R. J.u Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands.4 aut |
700 | 1 | a Bulitta, J. B.u Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Orlando, FL USA.4 aut |
700 | 1 | a Bassetti, M.u Santa Maria Misericordia Univ Hosp, Div Infect Dis, Udine, Italy.;Univ Udine, Udine, Italy.4 aut |
700 | 1 | a Theuretzbacher, U.u Ctr Anti Infect Agents, Vienna, Austria.4 aut |
700 | 1 | a Tsuji, B. T.u SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA.4 aut |
700 | 1 | a Wareham, D. W.u Queen Mary Univ London, Barts & London Sch Med & Dent, Antimicrobial Res Grp, London, England.4 aut |
700 | 1 | a Friberg, Lena Eu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo |
700 | 1 | a De Waele, J. J.u Ghent Univ Hosp, Dept Crit Care Med, Ghent, Belgium.4 aut |
700 | 1 | a Tam, V. H.u Univ Houston, Coll Pharm, Dept Pharm Practice & Translat Res, Houston, TX USA.4 aut |
700 | 1 | a Roberts, Jason A.u Univ Queensland, Trauma & Crit Care Res Ctr, Burns, Brisbane, Qld, Australia.;Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Brisbane, Qld, Australia.;Royal Brisbane & Womens Hosp, Dept Intens Care Med & Pharm, Level 3,Ned Hanlon Bldg, Brisbane, Qld 4029, Australia.4 aut |
710 | 2 | a Uppsala universitetb Infektionssjukdomar4 org |
773 | 0 | t Intensive Care Medicined : Springer Science and Business Media LLCg 43:7, s. 1021-1032q 43:7<1021-1032x 0342-4642x 1432-1238 |
856 | 4 | u https://www.research.manchester.ac.uk/portal/en/publications/the-role-of-infection-models-and-pkpd-modelling-for-optimising-care-of-critically-ill-patients-with-severe-infections(ef63d68d-b9bf-4957-8181-85a2b18ecb81).html |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-333824 |
856 | 4 8 | u https://doi.org/10.1007/s00134-017-4780-6 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy